• Clara Asifa
  • Rodiani Rodiani


Hypertension in pregnancy is one of the main cause of maternal death in the world. Hypertensive disorders in pregnancy, including preeclampsia, have a broad spectrum of conditions associated with maternal and fetal morbidity and mortality. Preeclampsia is a syndrome characterized by new onset of hypertension at ≥20 weeks of gestation, in pregnant women who were previously normotensive and accompanied by proteinuria. This paper aims to determine the effectiveness of docosahexaenoic acid (DHA) in pregnant women to prevent the risk of preeclampsia. This research method is to review the articles published in the last 10 years with the keywords preeclampsia, therapy, preventive, and docosahexaenoic acid (DHA). The data show that administration of docosahexaenoic acid (DHA) can reduce the risk of preeclampsia with minimal side effects for both maternal and the fetus. DHA on the other hand is still insignificant in preventing preeclampsia in high-risk pregnant women and prescribing the high dose of DHA is not recommended for pregnant women. DHA will be more effective in preventing preeclampsia if given in early pregnancy, especially in the first trimester of pregnancy


Download data is not yet available.


Mol BWJ, et al. Preeclampsia. Lancet. 2016;387(10022):999-1011.

WHO. Global Immunization Data. 2015.

Kemenkes RI. Profil Kesehatan Indonesia. Jakarta: Kementerian Kesehatan Republik Indonesia. 2014.

Kemenkes R. Kesehatan Dalam Kerangka Sustainable Development Goals (SDGs). 2015.

Jeyebalan A. Epidemiology of Preeclampsia; impact of obesity. Nutrition revies. 2013; 71 Suppl1(01), S18-S25.

Gathiram, P., & Moodley, J. Pre-eclampsia: Its pathogenesis and pathophysiolgy. Cardiovascular Journal of Africa. 2016;27(2):71-78.

Vata PK, Chauhan NM, Nallathambi A, Hussein F. Assessment of prevalence of preeclampsia from Dilla region of Ethiopia. BMC Research Notes.2015

Sohlberg, S., et al. Placental perfusion in normal pregnancy and early and late preeclampsia: A magnetic resonance imaging study. Placenta. 2014;35:202-206.

Wardhana MP, Dachlan EG, Dekker G. Pulmonary edema in preeclampsia an Indonesian case-control study. J Matern Neonatal Med. 2017;31(6):689-695.

Peres G, Mariana M, Cairrao E. Preeclampsia and eclampsia: An update on the pharmacological Treatment Applied in Portugal. J Cardiovasc Dev Dis. 2018;5(1):1-13.

Cifkova R. Why is the treatment of hypertension in pregnancy still so difficult? Expert Rev Cardiovasc Ther. 2011;9(6):647-649.

World Health Organization. WHO Recommendation for Prevention and Treatment of Pre-eclampsia and Eclampsia. 2011

Stevens W, et al. Short-term costs of preeclampsia to the United States health care system. Am J Obstet Gynecol. 2017;217(3):237-248.

Wright D., et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. Am J Obstet Gynecol. 2018;218(6):612.e1-e6.

Tranquilli A.L., et al. The classification diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014;4(2):97-104.

Magee L.A., et al. Diagnosis, evaluation, and management of the hypertensive disorder of pregnancy: executive summary. J Obstet Gynaecol Canada. 2014.36(5):416-436

Carvajal, J. A. Docosahexaenoic acid supplementation early in pregnancy may prevent deep placentation disorders. BioMed Research International. 2014;1-10.

Borhart J. Emergency department management of obstetric complications. Washington, DC: Springer International Publishing; 2017.

Rana, S., Lemoine, E., Granger, J. P., & Karumanchi, S. A. Preeclampsia. Circulation Research. 2019;124(7):1094-1112.

Brown, C. M., & Garovic, V. D. Mechanisms and management of hypertension in pregnant women. Curr Hyper Rep. 2011;13(5):338–46.

Sava, RI, March, KL, Pepine, CJ. Hypertension in pregnancy: Taking cues from pathophysiology for clinical practice. Clin Cardiol. 2018;41(2):221–28.

Calder P, C: Docosahexaenoic Acid. Ann Nutr Metab 2016;69(suppl 1):8-21.

M. L. Jones, P. J. Mark, T. A. Mori, J. A. Keelan, and B. J. Waddell. Maternal dietary omega-3 fatty acid supplementation reduces placental oxidative stress and increases fetal and placental growth in the rat. Biology of Reproduction. 2013;88(2):73.

Jones, M. L., Mark, P. J., Waddell, B. J. Maternal dietary omega-3 fatty acids and placental function. Reproduction. 2014;147(5).

Batista, A. C., et al. The Role Played by Salicylic Acid and Omega 3 in the Placental Vascular Resistance Mechanism: A Pilot Study. Clinics in Mother and Child Health. 2019;16(4):1-7.

Hubinont, C., & Savoye, T. Maternal and fetal benefits of DHA supplementation during pregnancy. Journal of Pregnancy and Reproduction, 1(1). 2017;1(1):2-7.

Bakouei, F., Delavar, M. A., Mashayekh-Amiri, S., Esmailzadeh, S., & Taheri, Z. (2020). Efficacy of n-3 fatty acids supplementation on the prevention of pregnancy induced-hypertension or preeclampsia: A systematic review and meta-analysis. Taiwanese Journal of Obstetrics and Gynecology. 2020;59(1):8-15.

Burchakov, D., Kuznetsova, I., & Uspenskaya, Y. Omega-3 Long-Chain Polyunsaturated Fatty Acids and Preeclampsia: Trials Say “No,” but Is It the Final Word? Nutrients. 2017;9(12):1364.

Abstract viewed = 187 times